{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:28:06Z","timestamp":1762918086762},"reference-count":77,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,5,19]]},"abstract":"<jats:sec><jats:title\/><jats:p>Cancer of the prostate are cancers in which most incidences are slow-growing, and in the U.S., a record of 1.2 million new cases of prostate cancer occurred in 2018. The rates of this type of cancer have been increasing in developing nations. The risk factors for prostate cancer include age, family history, and obesity. It is believed that the rate of prostate cancer is correlated with the Western diet. Various advances in methods of radiotherapy have contributed to lowering morbidity. Therapy for hormone- refractory prostate cancer is making progress, for almost all men with metastases will proceed to hormone-refractory prostate cancer. Smoking cigarettes along with the presence of prostate cancer has been shown to cause a higher risk of mortality in prostate cancer. The serious outcome of incontinence and erectile dysfunction result from the cancer treatment of surgery and radiation, particularly for prostate- specific antigen detected cancers that will not cause morbidity or mortality. Families of patients, as well as patients, are profoundly affected following the diagnosis of prostate cancer. Poor communication between spouses during prostate cancer increases the risk for poor adjustment to prostate cancer. The use of serum prostate-specific antigen to screen for prostate cancer has led to a greater detection, in its early stage, of this cancer. Prostate cancer is the most common malignancy in American men, accounting for more than 29% of all diagnosed cancers and about 13% of all cancer deaths. A shortened course of hormonal therapy with docetaxel following radical prostatectomy (or radiation therapy) for high-risk prostate cancer has been shown to be both safe and feasible. Patients treated with docetaxel-estramustine had a prostate-specific antigen response decline of at least 50%. Cancer vaccines are an immune-based cancer treatment that may provide the promise of a non-toxic but efficacious therapeutic alternative for cancer patients. Further studies will elucidate improved methods of detection and treatment.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1568026620666200224100730","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T14:21:24Z","timestamp":1582554084000},"page":"847-854","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prostate Cancer: Biology, Incidence, Detection Methods, Treatment Methods, and Vaccines"],"prefix":"10.2174","volume":"20","author":[{"given":"Ronald","family":"Bartzatt","sequence":"first","affiliation":[{"name":"Durham Science Center, College of Arts and Sciences, University of Nebraska at Omaha, 6001 Dodge Street, Omaha, Nebraska 68182, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780195175448.001.0001","author":"Ruddon R.W.","year":"2007","unstructured":"Ruddon R.W.; Cancer biology 2007","journal-title":"Cancer biology"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.mcna.2017.11.001","volume":"102","author":"Catalona W.J.","year":"2018","unstructured":"Catalona W.J.; Prostate cancer screening. Med Clin North Am 2018,102(2),199-214","journal-title":"Med Clin North Am"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","volume":"319","author":"Grossman D.C.","year":"2018","unstructured":"Grossman D.C.; Curry S.J.; Owens D.K.; Bibbins-Domingo K.; Caughey A.B.; Davidson K.W.; Doubeni C.A.; Ebell M.; Epling J.W.; Kemper A.R.; Krist A.H.; Kubik M.; Landefeld C.S.; Mangione C.M.; Silverstein M.; Simon M.A.; Siu A.L.; Tseng C.W.; US preventive services task force. screening for prostate cancer: us preventive services task force recommendation statement. JAMA 2018,319(18),1901-1913","journal-title":"JAMA"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/fampra\/cmq115","volume":"28","author":"Stratton J.","year":"2011","unstructured":"Stratton J.; Godwin M.; The effect of supplemental vitamins and minerals on the development of prostate cancer: a systematic review and meta-analysis. Fam Pract 2011,28(3),243-252","journal-title":"Fam Pract"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1177\/1557988318798279","volume":"12","author":"Taitt H.E.","year":"2018","unstructured":"Taitt H.E.; Global trends and prostrate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographical location. Am J Men Health 2018,12(6),1807-1823","journal-title":"Am J Men Health"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/cncr.11635","volume":"98","author":"Miller D.C.","year":"2003","unstructured":"Miller D.C.; Hafez K.S.; Stewart A.; Montie J.E.; Wei J.T.; Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer 2003,98(6),1169-1178","journal-title":"Cancer"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.2741\/1891","volume":"11","author":"Hsing A.W.","year":"2006","unstructured":"Hsing A.W.; Chokkalingam A.P.; Prostate cancer epidemiology. Front Biosci 2006,11,1388-1413","journal-title":"Front Biosci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1002\/cncr.11262","volume":"97","author":"Zeegers M.P.","year":"2003","unstructured":"Zeegers M.P.; Jellema A.; Ostrer H.; Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer 2003,97(8),1894-1903","journal-title":"Cancer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1056\/NEJMoa021423","volume":"348","author":"Calle E.E.","year":"2003","unstructured":"Calle E.E.; Rodriguez C.; Walker-Thurmond K.; Thun M.J.; Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003,348(17),1625-1638","journal-title":"N Engl J Med"},{"key":"ref=10","first-page":"242","volume":"11","author":"Wigle D.T.","year":"2008","unstructured":"Wigle D.T.; Turner M.C.; Goves J.; Parent M.E.; Role of hormonal and other factors in human prostate cancer. 2008, J. of Toxicology and Environmental Health part B. Crit Rev 2008,11(3-4),242-259","journal-title":"Crit Rev"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1001\/jama.291.13.1578","volume":"291","author":"Leitzmann M.F.","year":"2004","unstructured":"Leitzmann M.F.; Platz E.A.; Stampfer M.J.; Willett W.C.; Giovannucci E.; Ejaculation frequency and subsequent risk of prostate cancer. JAMA 2004,291(13),1578-1586","journal-title":"JAMA"},{"key":"ref=12","first-page":"130","volume":"28","author":"Li J.","year":"2016","unstructured":"Li J.; Wang Z.; The pathology of unusual subtypes of prostate cancer. Chin J Cancer Res 2016,28(1),130-143","journal-title":"Chin J Cancer Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.eururo.2012.11.012","volume":"63","author":"Masko E.M.","year":"2013","unstructured":"Masko E.M.; Allott E.H.; Freedland S.J.; The relationship between nutrition and prostate cancer: is more always better? Eur Urol 2013,63(5),810-820","journal-title":"Eur Urol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"Jemal A.","year":"2011","unstructured":"Jemal A.; Bray F.; Center M.M.; Ferlay J.; Ward E.; Forman D.; Global cancer statistics. CA Cancer J Clin 2011,61(2),69-90","journal-title":"CA Cancer J Clin"},{"key":"ref=15","author":"Bestwick D.G.","year":"2007","unstructured":"Bestwick D.G.; Eble J.N.; Urological surgical pathology 2007","journal-title":"Urological surgical pathology"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1136\/pmj.78.924.590","volume":"78","author":"Mazhar D.","year":"2002","unstructured":"Mazhar D.; Waxman J.; Prostate cancer. Postgrad Med J 2002,78(924),590-595","journal-title":"Postgrad Med J"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"Rawla P.","year":"2019","unstructured":"Rawla P.; Epidemiology of prostate cancer. World J Oncol 2019,10(2),63-89","journal-title":"World J Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"Siegel R.L.","year":"2019","unstructured":"Siegel R.L.; Miller K.D.; Jemal A.; Cancer statistics, 2019. CA Cancer J Clin 2019,69(1),7-34","journal-title":"CA Cancer J Clin"},{"key":"ref=19","first-page":"150","volume":"26","author":"Pollack A.","year":"1999","unstructured":"Pollack A.; Zagars G.K.; Rosen I.I.; Prostate cancer treatment with radiotherapy: maturing methods that minimize morbidity. Semin Oncol 1999,26(2),150-161","journal-title":"Semin Oncol"},{"key":"ref=20","first-page":"186","volume":"3","author":"Liberman D.","year":"2014","unstructured":"Liberman D.; Mehus B.; Elliott S.P.; Urinary adverse effects of pelvic radiotherapy. Transl Androl Urol 2014,3(2),186-195","journal-title":"Transl Androl Urol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1078-1439(99)00054-X","volume":"5","author":"Wang J.","year":"2000","unstructured":"Wang J.; Waxman J.; Chemotherapy for prostate cancer. Urol Oncol 2000,5(3),93-96","journal-title":"Urol Oncol"},{"key":"ref=22","first-page":"162","volume":"26","author":"Goktas S.","year":"1999","unstructured":"Goktas S.; Crawford E.D.; Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999,26(2),162-173","journal-title":"Semin Oncol"},{"key":"ref=23","first-page":"17","volume":"17","author":"Foroughi Moghadam M.J.","year":"2018","unstructured":"Foroughi Moghadam M.J.; Taheri S.; Peiravian F.; A systematic review of clinical practice guidelines for castration-resistant prostate cancer. Iran J Pharm Res 2018,17(Suppl.),17-37","journal-title":"Iran J Pharm Res"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jamaoncol.2019.1011","volume":"5","author":"Attard G.","year":"2019","unstructured":"Attard G.; Merseburger A.; Wiebki A.; Sternberg C.; Feyerabend S.; Berruti A.; Joniau S.; Geczi L.; Lefresne F.; Lahaye M.; Shelby F.; Pissart G.; Chua S.; Jones R.; Tombal B.; Assessment of the safety of glucocorticoid regimens in combination with abiraterone acetate for metastatic castration-resistant prostate cancer. JAMA Oncol 2019,5(8),1159-1167","journal-title":"JAMA Oncol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41391-019-0178-6","author":"Riviere P.","year":"2019","unstructured":"Riviere P.; Kumar A.; Luterstein E.; Vitzthum L.K.; Nalawade V.; Sarkar R.R.; Bryant A.K.; Einck J.P.; Mundt A.J.; Murphy J.D.; Rose B.S.; Tobacco smoking and death from prostate cancer in US veterans. Prostate Cancer Prostatic Dis 2019,1-8","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"ref=26","first-page":"260","volume":"77","author":"Magoha G.A.","year":"2000","unstructured":"Magoha G.A.; Management and survival in advanced prostate cancer in Nairobi. East Afr Med J 2000,77(5),260-263","journal-title":"East Afr Med J"},{"key":"ref=27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188258","volume":"12","author":"James L.J.","year":"2017","unstructured":"James L.J.; Wong G.; Craig J.C.; Hanson C.S.; Ju A.; Howard K.; Usherwood T.; Lau H.; Tong A.; Men\u2019s perspectives of prostate cancer screening: A systematic review of qualitative studies. PLoS One 2017,12(11)","journal-title":"PLoS One"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/pon.504","volume":"10","author":"Boehmer U.","year":"2001","unstructured":"Boehmer U.; Clark J.A.; Married couples\u2019 perspectives on prostate cancer diagnosis and treatment decision-making. Psychooncology 2001,10(2),147-155","journal-title":"Psychooncology"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/fampra\/cmm033","volume":"24","author":"Rai T.","year":"2007","unstructured":"Rai T.; Clements A.; Bukach C.; Shine B.; Austoker J.; Watson E.; What influences men\u2019s decision to have a prostate-specific antigen test? A qualitative study. Fam Pract 2007,24(4),365-371","journal-title":"Fam Pract"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1067\/mgn.2000.110836","volume":"21","author":"Weber B.A.","year":"2000","unstructured":"Weber B.A.; Roberts B.L.; McDougall G.J.; Exploring the efficacy of support groups for men with prostrate cancer. Geriatr Nurs 2000,21(5),250-253","journal-title":"Geriatr Nurs"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.33043\/JSACP.6.1.143-156","volume":"6","author":"Lacourt L.E.","year":"2014","unstructured":"Lacourt L.E.; Tackle prostate cancer: a doctoral student\u2019s response. J Soc Action Couns Psychol 2014,6(1),143-153","journal-title":"J Soc Action Couns Psychol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1053\/suro.2002.30398","volume":"20","author":"Manne S.L.","year":"2002","unstructured":"Manne S.L.; Prostate cancer support and advocacy groups: their role for patients and family members. Semin Urol Oncol 2002,20(1),45-54","journal-title":"Semin Urol Oncol"},{"key":"ref=33","first-page":"226","volume":"50","author":"Boehmer U.","year":"2001","unstructured":"Boehmer U.; Clark J.A.; Communication about prostate cancer between men and their wives. J Fam Pract 2001,50(3),226-231","journal-title":"J Fam Pract"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.mcna.2017.03.009","volume":"101","author":"Barry M.J.","year":"2017","unstructured":"Barry M.J.; Simmons L.H.; Prevention of prostate cancer morbidity and mortality: primary prevention and early detection. Med Clin North Am 2017,101(4),787-806","journal-title":"Med Clin North Am"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2296-8-35","volume":"8","author":"Clements A.","year":"2007","unstructured":"Clements A.; Watson E.; Rai T.; Bukach C.; Shine B.; Austoker J.; The PSA testing dilemma: GPs\u2019 reports of consultations with asymptomatic men: a qualitative study. BMC Fam Pract 2007,8,35-38","journal-title":"BMC Fam Pract"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1742-1241.2003.tb11395.x","volume":"57","author":"Little B.","year":"2003","unstructured":"Little B.; Young M.; How to use PSA to screen for prostate cancer. Int J Clin Pract 2003,57(1),40-42","journal-title":"Int J Clin Pract"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"920","DOI":"10.18632\/oncoscience.271","volume":"2","author":"Bonci D.","year":"2015","unstructured":"Bonci D.; De Maria R.; A predictive signature for therapy assignment and risk assessment in prostate cancer. Oncoscience 2015,2(11),920-923","journal-title":"Oncoscience"},{"key":"ref=38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186332","volume":"12","author":"Morlando M.","year":"2017","unstructured":"Morlando M.; Pelullo C.P.; Di Giuseppe G.; Prostate cancer screening: Knowledge, attitudes and practices in a sample of men in Italy. A survey. PLoS One 2017,12(10)","journal-title":"PLoS One"},{"key":"ref=39","first-page":"2","volume":"12","author":"Schr\u00f6der F.H.","year":"2005","unstructured":"Schr\u00f6der F.H.; Detection of prostate cancer: the impact of the European randomized study of screening for prostate cancer (ERSPC). Can J Urol 2005,12(Suppl. 1),2-6","journal-title":"Can J Urol"},{"key":"ref=40","first-page":"18","volume":"17","author":"Kell J.S.","year":"2010","unstructured":"Kell J.S.; Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians. Can J Urol 2010,17(Suppl. 1),18-25","journal-title":"Can J Urol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.urolonc.2009.12.019","volume":"30","author":"Tasian G.E.","year":"2012","unstructured":"Tasian G.E.; Cooperberg M.R.; Cowan J.E.; Keyashian K.; Greene K.L.; Daniels N.A.; Carroll P.R.; Chan J.M.; Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol 2012,30(2),155-160","journal-title":"Urol Oncol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"vii","DOI":"10.3310\/hta17200","volume":"17","author":"Mowatt G.","year":"2013","unstructured":"Mowatt G.; Scotland G.; Boachie C.; Cruickshank M.; Ford J.A.; Fraser C.; Kurban L.; Lam T.B.; Padhani A.R.; Royle J.; Scheenen T.W.; Tassie E.; The diagnostic accuracy and cost-effectiveness of magnetic resonance spectroscopy and enhanced magnetic resonance imaging techniques in aiding the localisation of prostate abnormalities for biopsy: a systematic review and economic evaluation. Health Technol Assess 2013,17(20),vii-xix, 1-281","journal-title":"Health Technol Assess"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/MOU.0000000000000668","volume":"29","author":"Giganti F.","year":"2019","unstructured":"Giganti F.; Moore C.M.; MRI in early detection of prostate cancer. Curr Opin Urol 2019,29(6),563-568","journal-title":"Curr Opin Urol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3322\/caac.20008","volume":"59","author":"Smith R.A.","year":"2009","unstructured":"Smith R.A.; Cokkinides V.; Brawley O.W.; Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009,59(1),27-41","journal-title":"CA Cancer J Clin"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3322\/canjclin.53.1.27","volume":"53","author":"Smith R.A.","year":"2003","unstructured":"Smith R.A.; Cokkinides V.; Eyre H.J.; American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin American Cancer Society2003,53(1),27-43","journal-title":"CA Cancer J Clin"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.52.1.8","volume":"52","author":"Smith R.A.","year":"2002","unstructured":"Smith R.A.; Cokkinides V.; von Eschenbach A.C.; Levin B.; Cohen C.; Runowicz C.D.; Sener S.; Saslow D.; Eyre H.J.; American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin American Cancer Society2002,52(1),8-22","journal-title":"CA Cancer J Clin"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.suc.2015.05.001","volume":"95","author":"Tabayoyong W.","year":"2015","unstructured":"Tabayoyong W.; Abouassaly R.; Prostate cancer screening and the associated controversy. Surg Clin North Am 2015,95(5),1023-1039","journal-title":"Surg Clin North Am"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3816\/CGC.2003.n.015","volume":"2","author":"Moul J.W.","year":"2003","unstructured":"Moul J.W.; Population screening for prostate cancer and emerging concepts for young men. Clin Prostate Cancer 2003,2(2),87-97","journal-title":"Clin Prostate Cancer"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00345-011-0795-8","volume":"30","author":"Vickers A.J.","year":"2012","unstructured":"Vickers A.J.; Lilja H.; Predicting prostate cancer many years before diagnosis: how and why? World J Urol 2012,30(2),131-135","journal-title":"World J Urol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/CEJ.0000000000000149","volume":"25","author":"Pinto \u00c1.","year":"2016","unstructured":"Pinto \u00c1.; P\u00e9rez Segura P.; Primary prevention and early diagnosis of prostate cancer: recommendations from the prevention and early diagnosis working group of the Spanish Society of Medical Oncology (SEOM). Eur J Cancer Prev 2016,25(2),137-141","journal-title":"Eur J Cancer Prev"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.urology.2014.02.035","volume":"83","author":"Ankerst D.P.","year":"2014","unstructured":"Ankerst D.P.; Hoefler J.; Bock S.; Goodman P.J.; Vickers A.; Hernandez J.; Sokoll L.J.; Sanda M.G.; Wei J.T.; Leach R.J.; Thompson I.M.; Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology 2014,83(6),1362-1367","journal-title":"Urology"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S2173-5786(10)70169-4","volume":"34","author":"Ruiz-Arag\u00f3n J.","year":"2010","unstructured":"Ruiz-Arag\u00f3n J.; M\u00e1rquez-Pel\u00e1ez S.; Luque Romero L.G.; [Erectile dysfunction in patients with prostate cancer who have undergone surgery: Systematic review of literature]. Actas Urol Esp 2010,34(8),677-685","journal-title":"Actas Urol Esp"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5534\/wjmh.2012.30.2.99","volume":"30","author":"Hyun J.S.","year":"2012","unstructured":"Hyun J.S.; Prostate cancer and sexual function. World J Mens Health 2012,30(2),99-107","journal-title":"World J Mens Health"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2174\/1876822901003010099","volume":"3","author":"Bazan J.G.","year":"2010","unstructured":"Bazan J.G.; King C.R.; Brooks J.D.; Srinivas S.; Adjuvant docetaxel and abbreviated androgen deprivation therapy in patients with high risk prostate cancer. Open Prostate Cancer J 2010,3,99-104","journal-title":"Open Prostate Cancer J"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00042307-200405000-00007","volume":"14","author":"Holzbeierlein J.M.","year":"2004","unstructured":"Holzbeierlein J.M.; McLaughlin M.D.; Thrasher J.B.; Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 2004,14(3),177-183","journal-title":"Curr Opin Urol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1876822901306010001","volume":"6","author":"Sieh W.","year":"2013","unstructured":"Sieh W.; Lichtensztajn D.Y.; Nelson D.O.; Cockburn M.; West D.W.; Brooks J.D.; Chang E.T.; Treatment and mortality in men with localized prostate cancer: a population based study in California. Open Prostate Cancer J 2013,6,1-9","journal-title":"Open Prostate Cancer J"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"Siegel R.","year":"2012","unstructured":"Siegel R.; Naishadham D.; Jemal A.; Cancer statistics, 2012. CA Cancer J Clin 2012,62(1),10-29","journal-title":"CA Cancer J Clin"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1056\/NEJMe1100787","volume":"364","author":"Smith M.R.","year":"2011","unstructured":"Smith M.R.; Effective treatment for early-stage prostate cancer--possible, necessary, or both? N Engl J Med 2011,364(18),1770-1772","journal-title":"N Engl J Med"},{"key":"ref=59","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/4520645","volume":"2019","author":"Lodise O.","year":"2019","unstructured":"Lodise O.; Patil K.; Karshenboym I.; Prombo S.; Chukwueke C.; Pai S.B.; Inhibition of prostate cancer cells by 4,5-dicaffeoylquinic acid through cell cycle arrest. Prostate Cancer 2019,2019","journal-title":"Prostate Cancer"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jsbmb.2004.10.005","volume":"92","author":"Tammela T.","year":"2004","unstructured":"Tammela T.; Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004,92(4),287-295","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=61","first-page":"1507","volume":"32","author":"Akaza H.","year":"2005","unstructured":"Akaza H.; Chodak G.W.; Hirao Y.; [Usefulness and positioning of MAB therapy for prostate cancer]. Gan To Kagaku Ryoho 2005,32(10),1507-1520","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref=62","first-page":"43","volume":"30","author":"Sakai H.","year":"2003","unstructured":"Sakai H.; Kanetake H.; [First line therapy in the treatment of metastatic prostate cancer]. Gan To Kagaku Ryoho 2003,30(1),43-49","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0094-0143(02)00007-1","volume":"29","author":"Sessions A.E.","year":"2002","unstructured":"Sessions A.E.; Messing E.M.; Timing hormonal therapy in prostate cancer. Urol Clin North Am 2002,29(1),223-227","journal-title":"Urol Clin North Am"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ijrobp.2010.10.009","volume":"82","author":"Mohammed N.","year":"2012","unstructured":"Mohammed N.; Kestin L.; Ghilezan M.; Krauss D.; Vicini F.; Brabbins D.; Gustafson G.; Ye H.; Martinez A.; Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012,82(1),204-212","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/jjco\/hyn056","volume":"38","author":"Fang F.M.","year":"2008","unstructured":"Fang F.M.; Wang Y.M.; Wang C.J.; Huang H.Y.; Chiang P.H.; Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Jpn J Clin Oncol 2008,38(7),474-479","journal-title":"Jpn J Clin Oncol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1200\/JCO.2005.06.154","volume":"23","author":"Sathya J.R.","year":"2005","unstructured":"Sathya J.R.; Davis I.R.; Julian J.A.; Guo Q.; Daya D.; Dayes I.S.; Lukka H.R.; Levine M.; Randomized trial comparing iridium implant plus external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005,23(6),1192-1196","journal-title":"J Clin Oncol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.urology.2005.04.020","volume":"65","author":"Petrylak D.P.","year":"2005","unstructured":"Petrylak D.P.; Future directions in the treatment of androgen-independent prostate cancer. Urology 2005,65(6)(Suppl.),8-12","journal-title":"Urology"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/cncr.22439","volume":"109","author":"Oh W.K.","year":"2007","unstructured":"Oh W.K.; Tay M.H.; Huang J.; Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007,109(3),477-486","journal-title":"Cancer"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000084201","volume":"68","author":"Sternberg C.N.","year":"2005","unstructured":"Sternberg C.N.; Whelan P.; Hetherington J.; Paluchowska B.; Slee P.H.; Vekemans K.; Van Erps P.; Theodore C.; Koriakine O.; Oliver T.; Lebwohl D.; Debois M.; Zurlo A.; Collette L.; Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology Genitourinary Tract Group of the EORTC2005,68(1),2-9","journal-title":"Oncology"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11934-009-0072-1","volume":"10","author":"Rhoden E.L.","year":"2009","unstructured":"Rhoden E.L.; Averbeck M.A.; Testosterone therapy and prostate carcinoma. Curr Urol Rep 2009,10(6),453-459","journal-title":"Curr Urol Rep"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"878","DOI":"10.4103\/1008-682X.150841","volume":"17","author":"Warburton D.","year":"2015","unstructured":"Warburton D.; Hobaugh C.; Wang G.; Lin H.; Wang R.; Testosterone replacement therapy and the risk of prostate cancer. Asian J Androl 2015,17(6),878-881","journal-title":"Asian J Androl"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2017.7248","volume":"317","author":"Litwin M.S.","year":"2017","unstructured":"Litwin M.S.; Tan H.J.; The diagnosis and treatment of prostate cancer. JAMA 2017,317(24),2532-2542","journal-title":"JAMA"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00262-015-1667-7","volume":"64","author":"Baxevanis C.N.","year":"2015","unstructured":"Baxevanis C.N.; Papamichail M.; Perez S.A.; Prostate cancer vaccines: the long road to clinical application. Cancer Immunol Immunother 2015,64(4),401-408","journal-title":"Cancer Immunol Immunother"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.urolonc.2017.09.024","volume":"35","author":"Redman J.M.","year":"2017","unstructured":"Redman J.M.; Gulley J.L.; Madan R.A.; Combining immunotherapies for the treatment of prostate cancer. Urol Oncol 2017,35(12),694-700","journal-title":"Urol Oncol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2217\/14796694.5.2.187","volume":"5","author":"Arlen P.M.","year":"2009","unstructured":"Arlen P.M.; Mohebtash M.; Madan R.A.; Gulley J.L.; Promising novel immunotherapies and combinations for prostate cancer. Future Oncol 2009,5(2),187-196","journal-title":"Future Oncol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.2174\/187152009789735062","volume":"9","author":"Arlen P.M.","year":"2009","unstructured":"Arlen P.M.; Gulley J.L.; Current perspectives in prostate cancer vaccines. Anticancer Agents Med Chem 2009,9(10),1052-1057","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=77","first-page":"31","volume":"11","author":"Mohebtash M.","year":"2009","unstructured":"Mohebtash M.; Gulley J.L.; Madan R.A.; Ferrara T.; Arlen P.M.; Cancer vaccines: current directions and perspectives in prostate cancer. Curr Opin Mol Ther 2009,11(1),31-36","journal-title":"Curr Opin Mol Ther"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/179650","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T01:02:05Z","timestamp":1722474125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/179650\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,5,19]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200224100730","relation":{},"ISSN":["1568-0266"],"issn-type":[{"type":"print","value":"1568-0266"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}